Four new medicines available via NHS Scotland
The Scottish Medicines Consortium has cleared funds for use of four new medicines by NHS Scotland, including Sanofi’s biologic Dupixent for dermatitis.
Read More
Tag: Roactemra
CAR-T therapies leap towards EU approval
The stage has been set for approval of the first chimeric antigen T-cell therapies (CAR-T) in Europe, after Novartis’ Kymriah and Gilead’s Yescarta both won backing from the Committee for Medicinal Products for Human Use (CHMP).
Read More
Final NHS nod for Roche’s RoActemra
Roche/Chugai’s RoActemra should be routinely offered throughout the NHS to adults with giant cell arteritis (GCA) within the next three months, following a final green light from cost regulators.
Read More
NICE u-turn on treatment for giant cell arteritis
Roche/Chugai’s RoActemra has now won the backing of the National Institute of Health and Care Excellence for the treatment of eligible patients with giant cell arteritis (GCA).
Read More
NHS use of Roche’s Roactemra turned down for giant cell arteritis
It is looking unlikely that patients with giant cell arteritis will get NHS access to Roche’s Roactemra, after the drug was turned down by cost regulators in draft guidelines.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
